These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21423209)

  • 1. β-Catenin is required for Ron receptor-induced mammary tumorigenesis.
    Wagh PK; Gray JK; Zinser GM; Vasiliauskas J; James L; Monga SP; Waltz SE
    Oncogene; 2011 Aug; 30(34):3694-704. PubMed ID: 21423209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.
    Benight NM; Wagh PK; Zinser GM; Peace BE; Stuart WD; Vasiliauskas J; Pathrose P; Starnes SL; Waltz SE
    Oncotarget; 2015 Jul; 6(19):17445-61. PubMed ID: 25938541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis.
    Wagh PK; Zinser GM; Gray JK; Shrestha A; Waltz SE
    Endocrinology; 2012 Jun; 153(6):2735-46. PubMed ID: 22474186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.
    Johnson AL; Zinser GM; Waltz SE
    Oncotarget; 2015 Jun; 6(18):16304-20. PubMed ID: 26008979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.
    Wagh PK; Peace BE; Waltz SE
    Adv Cancer Res; 2008; 100():1-33. PubMed ID: 18620091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
    Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
    Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.
    Zinser GM; Leonis MA; Toney K; Pathrose P; Thobe M; Kader SA; Peace BE; Beauman SR; Collins MH; Waltz SE
    Cancer Res; 2006 Dec; 66(24):11967-74. PubMed ID: 17178895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.
    Xu XM; Zhou YQ; Wang MH
    J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.
    Danilkovitch-Miagkova A; Miagkov A; Skeel A; Nakaigawa N; Zbar B; Leonard EJ
    Mol Cell Biol; 2001 Sep; 21(17):5857-68. PubMed ID: 11486025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.
    Ruiz-Torres SJ; Benight NM; Karns RA; Lower EE; Guan JL; Waltz SE
    Oncotarget; 2017 Aug; 8(35):58918-58933. PubMed ID: 28938607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer.
    Peace BE; Toney-Earley K; Collins MH; Waltz SE
    Cancer Res; 2005 Feb; 65(4):1285-93. PubMed ID: 15735014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
    McClaine RJ; Marshall AM; Wagh PK; Waltz SE
    Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.
    Zhao H; Chen MS; Lo YH; Waltz SE; Wang J; Ho PC; Vasiliauskas J; Plattner R; Wang YL; Wang SC
    Oncogene; 2014 Mar; 33(11):1429-37. PubMed ID: 23542172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.
    Gurusamy D; Ruiz-Torres SJ; Johnson AL; Smith DA; Waltz SE
    Mech Dev; 2014 Aug; 133():11-22. PubMed ID: 25049204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
    Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
    Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
    Iwama A; Yamaguchi N; Suda T
    EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer.
    Pond AC; Herschkowitz JI; Schwertfeger KL; Welm B; Zhang Y; York B; Cardiff RD; Hilsenbeck S; Perou CM; Creighton CJ; Lloyd RE; Rosen JM
    Cancer Res; 2010 Jun; 70(12):4868-79. PubMed ID: 20501844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
    Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
    Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype.
    Roarty K; Baxley SE; Crowley MR; Frost AR; Serra R
    Breast Cancer Res; 2009; 11(2):R19. PubMed ID: 19344510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.